Although it will need to be further tested before being ready for clinical use, it could potentially improve treatment for Type I diabetes.
The approach was found to increase drug efficacy; it is concentrated at target sites, such as regions of the pancreas that contain the insulin-producing cells.
The dramatic increase in efficacy also means that much smaller amounts of drugs would be needed for treatment, opening the possibility of significantly reduced toxic side effects, as well as lower treatment costs.
Using nanoparticles that can be programmed to deliver drug or stem cell therapies to specific disease sites is an excellent alternative to systemic treatments because improved responses can be obtained with significantly lower therapeutic doses and hence, fewer side effects.
